Method for Screening for Cancer Theraputics by Detection of Early DNA Damage

Inventors: Thanos Halazonetis and Linda Schultz

Tech ID: HT-00001

Description: A protein that selectively binds to p53 (53BP1) has been demonstrated to have a role in the cellular response to DNA damage. In untreated primary cells stained with antibodies to 53BP1, a diffuse nuclear staining pattern is observed. When these cells are exposed to ionizing radiation, the 53BP1 localizes into discrete nuclear foci within 5 to 15 minutes. These foci represent sites of processing of double-stranded DNA breaks. The onset of changes in 53BP1 staining occurs much earlier than other indicators of DNA damage, and, therefore may be useful in rapid screening assays for cancer therapeutic agents.

Wistar scientists have developed high affinity antibodies to 53BP1 which can be used in screening assays to detect the onset and prevention of DNA damage.

Key Words: Screening, target, cancer, diagnostic, HTS

Applications and Advantages: 53bp1 may be useful in the development of screening assays to identify compounds that correct or prevent DNA-damage or for the development of novel diagnostics to predict DNA-damaged cells which are precursors of cancerous cells.

Intellectual Property Status: US and International patent applications have been filed (10/276,312, PCT/US01/1747,).

Licensing Opportunity: This technology is available for exclusive or non-exclusive license. Sponsored research support to further develop the technology will also be considered.

Relevant Publications: Schultz, et al., J. Cell. Biology, 151, 1381-1390. 2000.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last Updated: Aug-02